CatalystAlert

Search CatalystAlert

Search for companies, drugs, and catalysts

Search CatalystAlert

Search for companies, drugs, and catalysts

PR Newswire Biotech
Original article

Halozyme Therapeutics, Inc. Announces Pricing of Upsized Private Offering of $1.3 Billion of Convertible Senior Notes due 2033

Neutral
AI Analysis

Summary

Halozyme Therapeutics announced the pricing of $1.3 billion in convertible senior notes due 2033 at 1.50% interest, with the offering size increased from its original amount.

Importance:6/10
Sentiment:
0.00
convertible notesdebt offeringcapital raise
Related Companies

Read the original article

Published by PR Newswire Biotech on September 18, 2026 3:20 AM

Read Original